Evidence map›Paper›PMID 34086544›Full record

ArticlePathogens and global health2022

Significance of the coexistence of non-codon 315 katG, inhA, and oxyR-ahpC intergenic gene mutations among isoniazid-resistant and multidrug-resistant isolates of Mycobacterium tuberculosis: a report of novel mutations.

Fatemeh Norouzi, Sharareh Moghim, ShimaSadat Farzaneh, Hossein Fazeli, Mahshid Salehi, Bahram Nasr Esfahani

Open access · greenAbstract read
In one paragraph

Article in Pathogens and global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Mutations inInfection and drug resistance · 2026
    Article
  3. Selection of Multi-Drug Targets against Drug-ResistantInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fatemeh NorouziDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-7078-3616
Sharareh MoghimDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-7134-3145
ShimaSadat FarzanehDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-2798-7904
Hossein FazeliDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-1188-8012
Mahshid SalehiRegional Tuberculosis Reference Laboratories in Isfahan, Isfahan, Iran.ORCID 0000-0002-5219-7648
Bahram Nasr EsfahaniDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0003-3264-3361
Isfahan University of Medical Sciences · IRUniversity of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is a global threat due to the emergence and spread of drug-resistant

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsDNA, BacterialDNA, IntergenicHumansIsoniazidMicrobial Sensitivity TestsMutationAntitubercular AgentsBacterial ProteinsDNA, BacterialDNA, IntergenicIsoniazidinhAIsoniazid resistancekatGMycobacterium tuberculosisoxyR-ahpC

Identifiers

PMID34086544
PMCPMC8812758
OpenAlexW3165208502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.